“We pursue scientific and technological innovations to explore new ways to further reduce animal use.” Hear from Professor Julie Frearson, PhD in Genetic Engineering & Biotechnology News. #3Rs #alternatives #AMAP https://okt.to/hNt4ys
Charles River Laboratories’ Post
More Relevant Posts
-
Exciting News!😊 I’m thrilled to announce that our latest research paper, titled “Exonisation of an intronic L1 element in the dystrophin gene associated with X-linked muscular dystrophy in a Border Collie dog,” has been published online in Animal Genetics. This research investigates the genetic origins of muscular dystrophy in a Border Collie, providing insights that could contribute to future research and understanding of similar conditions. You can read the full paper here: https://lnkd.in/eFrriCyD
Exonisation of an intronic L1 element in the dystrophin gene associated with X‐linked muscular dystrophy in a Border Collie dog
onlinelibrary.wiley.com
To view or add a comment, sign in
-
If anything, however, the problem is likely to worsen. The use of #genetically altered animals in #biomedicalresearch is set to explode because creating them is getting ever easier and cheaper, courtesy of new gene-editing techniques. If we’re not vigilant, ever more #publicmoney will be squandered on esoteric research into the unique quirks of genetically modified animals, with little relevance to humans. That is not fair on #taxpayers or the #animals themselves. Animal research is only #ethicallyjustified when it produces clear benefits for humanity. It is also grossly unfair to those people the research is meant to benefit. As Garner puts it: “Once you start meeting patients, you realise the urgency of getting this right.” This article appeared in print under the headline “Man or mouse?” https://lnkd.in/eq5gZe3B
Man or mouse? Why drug research has taken the wrong turning
newscientist.com
To view or add a comment, sign in
-
The move to more relevant, better in vitro models of human disease. We were excited to read this new article in Genetic Engineering and Biotechnology news, which discusses how developments such as the FDA Modernization Act 2.0 and the animal welfare principles known as the “3Rs” (reduction, replacement, and refinement) are challenging the entrenchment of in vivo animal models in preclinical work and encouraging the development of alternative models. Companies are using scientific and technological innovations to explore new ways to further reduce animal use and produce more human-relevant models for drug discovery and research. To realize the potential, the industry requires a consistent supply of functional end-point cells reflecting the phenotype of their donor and the ability to co-culture multiple cells. Click here to read the full article: https://hubs.la/Q02KPR5F0 At Axol, we have gained an international reputation for the production and characterization of functional, high quality iPSC-derived cells over the last decade. If you are interested in using axoCells iPSC-derived cells to develop human-relevant models for drug discovery and research, contact us at [email protected] #iPSCs #DrugDiscovery #StemCells #biopharma
Animal Models and Their Alternatives Share the Preclinical Habitat
genengnews.com
To view or add a comment, sign in
-
The move to more relevant, better in vitro models of human disease. We were excited to read this new article in Genetic Engineering and Biotechnology news, which discusses how developments such as the FDA Modernization Act 2.0 and the animal welfare principles known as the “3Rs” (reduction, replacement, and refinement) are challenging the entrenchment of in vivo animal models in preclinical work and encouraging the development of alternative models. Companies are using scientific and technological innovations to explore new ways to further reduce animal use and produce more human-relevant models for drug discovery and research. To realize the potential, the industry requires a consistent supply of functional end-point cells reflecting the phenotype of their donor and the ability to co-culture multiple cells. Click here to read the full article: https://hubs.la/Q02KPPR90 At Axol, we have gained an international reputation for the production and characterization of functional, high quality iPSC-derived cells over the last decade. If you are interested in using axoCells iPSC-derived cells to develop human-relevant models for drug discovery and research, contact us at [email protected] #iPSCs #DrugDiscovery #StemCells #biopharma
Animal Models and Their Alternatives Share the Preclinical Habitat
genengnews.com
To view or add a comment, sign in
-
🔬 As I'm dedicated to advancing treatments for kidney disease to reduce human suffering, I'm always on the lookout for innovative approaches that can enhance our research while reducing reliance on animal models. That's why I'm particularly excited about the potential of human nano biopsies and spheroids in our field. A recent Nature article (https://lnkd.in/eRyXT-j2) highlights a critical issue: use of animals, often mice, is counterproductive in biomedical research. A staggering 90% of treatments that work in mice fail to translate to treatments for humans. This is largely due to the vast differences between mouse and human immune systems. In my lab, we're pioneering the use of human spheroids to test drugs for kidney disease. This approach not only promises more accurate results but also aligns with our ethical commitment to minimise animal testing. I'm especially intrigued by the potential of human nano biopsies. These tiny tissue samples could revolutionise our ability to gather crucial data, with minimal invasiveness, offering a more humane and potentially more effective path forward in kidney disease research. Let's continue pushing the boundaries of science while prioritising ethical, human-relevant research methods! #KidneyResearch #EthicalScience #NanoBiopsies #HumanSpheroids #BiomedicalInnovation
Animal research is not always king: researchers should explore the alternatives
nature.com
To view or add a comment, sign in
-
#preventive_animal_health Is feed efficiency (FE), a trait of your interest? Do you know which #research #model 🔬 can help you to gain insights into complex biological mechanisms such as FE? 🤔 Our findings demonstrate that compare to low FE pigs 🐷, high FE pigs showed less pronounced immune response when challenged with adherent and invasive E. coli. Using #organoids, our unique in vitro 🔬 cell culture based model, we gained insights into complex biological mechanisms such as FE. Read more about the findings, in our latest publication 👇🏽 https://lnkd.in/eSj62GrW Ole Madsen, Roxann R., Jerry Wells, Esther Ellen, Henri Woelders. #3Rs_in_animal_experiment, #invitromodels, #NAMs (new approach methods), #animal_genetics, #host_microbe_interactions Wageningen Livestock Research; Wageningen Animal Sciences
Transcriptomic analysis of intestinal organoids, derived from pigs divergent in feed efficiency, and their response to Escherichia coli - BMC Genomics
bmcgenomics.biomedcentral.com
To view or add a comment, sign in
-
A year after President Joe Biden signed a groundbreaking law, researchers can now test drug candidates on human tissue or computer models before moving to clinical trials. This monumental shift challenges the long-standing regulatory norm requiring animal testing, opening doors for more innovative and humane research methods. Human tissues, induced pluripotent stem cells and 3D engineered tissues such as organoids are leading the charge, offering more accurate and human-relevant data. These advancements are crucial in immunology and personalized medicine, where human-specific responses are essential. Animal studies remain vital in later stages of drug development, but reducing reliance on them, especially in early-stage research, is a significant step forward. This change not only accelerates the drug discovery process but also aligns with ethical standards and improves the emotional well-being of researchers. The FDA’s new mandate is a call to action for researchers to embrace and validate these alternative methods for a more promising future in drug discovery. Read more here: https://hubs.li/Q02H3nfw0 #drugdiscovery #animaltesting #humantissue #engineeredtissue
Animal research is not always king: researchers should explore the alternatives
nature.com
To view or add a comment, sign in
-
Join Charles River Laboratories for this webinar as they focus on managing genetically engineered models while being mindful of the 4Rs. Look at ways you can reduce colony size and support the wellbeing of research animals by discussing these topics: -Innovative management tools, training, and SOPs -Efficient embryology and genotyping refinements -Pioneering techniques for model generation https://lnkd.in/eTmYfBhX
Managing Genetically Engineered Animals Through the Lens of the 4Rs
criver.com
To view or add a comment, sign in
-
Why do we value industry collaborations and partnerships? Benchmark engages in a dynamic blend of internal R&D and collaborative worldwide initiatives with leading researchers, universities, and companies. 🧬 Our collaborative partnerships providing robust support to some of our most important R&D projects, allowing us to access additional leading expertise and funding. This way, we are continually developing and delivering cutting-edge products and services, maintaining our standing in the scientific community. We are proud to partner with the Havforskningsinstituttet (gene editing and sterility); Nofima (genomic selection, gene editing); Roslin Institute (genomics and disease resistance); and @Háskóli Íslands (sterility in salmon). ➡️ Keep an eye on our innovation news page for the latest updates: https://lnkd.in/eeftFmwq #IndustryCollaberation #Innovation #SustainableAquaculture Benchmark Genetics Norway AS Benchmark Genetics Shrimp Benchmark Genetics Iceland Benchmark Genetics Chile Benchmark Animal Health INVE Aquaculture
To view or add a comment, sign in
-
-
A recently published collaborative study with the Université de Namur-Namur Research Institute for Life Sciences (NARILIS), co-authored by AvantBio’s CEO, Dr. Paul W. Cook and others (Julia Bajsert · Yves Poumay · Valérie De Glas · Emilie Faway · Miguel Aso Perez, PhD · Catherine Lambert de Rouvroit) represents a significant step forward regarding the characterization of AvantBio’s improved chemically defined animal origin-free (cdAOF) HKSdaFREE kit supplement system for human keratinocytes and corneal epithelial cells. This system allows for the efficient reconstruction of human tissue under cdAOF conditions, in this case, cdAOF reconstructed human epidermis (RHE). This cdAOF system was designed for safer (pathogen-free) cutaneous regenerative medicine, and now may have utility for animal cruelty-free RHE testing, in vitro. Through R&D, we are currently looking forward to further improvement in the cdAOF RHE system as well as the reconstruction of cdAOF full-thickness human skin equivalents and human corneal epithelium. To learn more about the reconstruction of human epidermis (RHE) under chemically defined animal origin-free (cdAOF) conditions, please see: https://lnkd.in/gHXNra2E
CHARACTERIZATION OF RECONSTRUCTED HUMAN EPIDERMIS IN A CHEMICALLY-DEFINED, ANIMAL ORIGIN-FREE CELL CULTURE
jidinnovations.org
To view or add a comment, sign in